BridgeBio Pharma

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade BridgeBio Pharma 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BBIO

BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. 

CEO
Neil Kumar
CEONeil Kumar
Employees
730
Employees730
Headquarters
Palo Alto, California
HeadquartersPalo Alto, California
Founded
2015
Founded2015
Employees
730
Employees730

BBIO Key Statistics

Market cap
15.29B
Market cap15.29B
Price-Earnings ratio
-18.17
Price-Earnings ratio-18.17
Dividend yield
Dividend yield
Average volume
3.78M
Average volume3.78M
High today
$78.06
High today$78.06
Low today
$72.82
Low today$72.82
Open price
$76.22
Open price$76.22
Volume
1.67M
Volume1.67M
52 Week high
$84.94
52 Week high$84.94
52 Week low
$28.33
52 Week low$28.33

Stock Snapshot

As of today, BridgeBio Pharma(BBIO) shares are valued at $76.51. The company's market cap stands at 15.29B, with a P/E ratio of -18.17.

As of 2026-02-13, BridgeBio Pharma(BBIO) stock has fluctuated between $72.82 and $78.06. The current price stands at $76.51, placing the stock +5.1% above today's low and -2.0% off the high.

The BridgeBio Pharma(BBIO)'s current trading volume is 1.67M, compared to an average daily volume of 3.78M.

During the past year, BridgeBio Pharma(BBIO) stock moved between $28.33 at its lowest and $84.94 at its peak.

During the past year, BridgeBio Pharma(BBIO) stock moved between $28.33 at its lowest and $84.94 at its peak.

BBIO News

TipRanks 21h
BridgeBio Announces Positive Phase 3 Achondroplasia Trial Results

The latest update is out from BridgeBio Pharma ( (BBIO) ). On February 12, 2026, BridgeBio reported positive topline results from its global Phase 3 PROPEL 3 t...

Analyst ratings

96%

of 24 ratings
Buy
95.8%
Hold
4.2%
Sell
0%

People also own

Based on the portfolios of people who own BBIO. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.